CDNA Stock Overview
Engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CareDx, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.01 |
| 52 Week High | US$17.03 |
| 52 Week Low | US$4.80 |
| Beta | 1.51 |
| 1 Month Change | 41.72% |
| 3 Month Change | 8.33% |
| 1 Year Change | 60.02% |
| 3 Year Change | -83.93% |
| 5 Year Change | -65.20% |
| Change since IPO | 30.10% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge
Apr 27
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
Mar 02CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry
Dec 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27Benign Growth For CareDx, Inc (NASDAQ:CDNA) Underpins Its Share Price
Jun 29Analyst Forecasts Just Became More Bearish On CareDx, Inc (NASDAQ:CDNA)
May 16CareDx: Shaking Off First-Mover Disadvantage
Oct 18CareDx: Best Near Cap-Gain Health Diagnostics Prospect Say Market Makers
Aug 08Shareholder Returns
| CDNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -18.4% | -0.3% | -0.6% |
| 1Y | 60.0% | 5.4% | 22.3% |
Return vs Industry: CDNA exceeded the US Biotechs industry which returned 4.7% over the past year.
Return vs Market: CDNA exceeded the US Market which returned 21.5% over the past year.
Price Volatility
| CDNA volatility | |
|---|---|
| CDNA Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CDNA's share price has been volatile over the past 3 months.
Volatility Over Time: CDNA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 639 | John Hanna | caredx.com |
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software.
CareDx, Inc Fundamentals Summary
| CDNA fundamental statistics | |
|---|---|
| Market cap | US$704.17m |
| Earnings (TTM) | -US$183.19m |
| Revenue (TTM) | US$275.11m |
2.5x
P/S Ratio-3.7x
P/E RatioIs CDNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDNA income statement (TTM) | |
|---|---|
| Revenue | US$275.11m |
| Cost of Revenue | US$101.97m |
| Gross Profit | US$173.14m |
| Other Expenses | US$356.34m |
| Earnings | -US$183.19m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.52 |
| Gross Margin | 62.94% |
| Net Profit Margin | -66.59% |
| Debt/Equity Ratio | 0% |
How did CDNA perform over the long term?
See historical performance and comparison